Baseline characteristics of hepatocellular carcinoma patients treated with nivolumab
| Baseline characteristic | N (%) |
| Total | 233 (100) |
| Age in years, median (IQR) | 64 (56–69) |
| Gender | |
| Male | 184 (79.0) |
| Female | 49 (21.0) |
| Cirrhosis | |
| Present | 176 (75.5) |
| Absent | 57 (24.5) |
| Etiology of chronic liver disease | |
| HCV | 95 (40.8) |
| HBV | 83 (35.6) |
| Alcohol | 29 (12.4) |
| NASH | 24 (10.3) |
| Other | 10 (4.3) |
| Child-Pugh class | |
| A | 158 (67.8) |
| B | 75 (32.2) |
| Albumin (g/L), median (IQR) | 35 (30–39) |
| Bilirubin (mmol/L), median (IQR) | 15 (10–24) |
| ALT (IU/L), median (IQR) | 47 (30–78) |
| ALP (IU/L), median (IQR) | 147.5 (93.3–228.8) |
| Platelet count, median (IQR) (n=139) | 142 (96.5–212.5) |
| Barcelona clinic liver cancer stage | |
| A | 4 (1.7) |
| B | 23 (9.9) |
| C | 204 (87.8) |
| D | 2 (0.6) |
| ECOG performance status | |
| 0 | 44 (28.0) |
| 1 | 99 (63.1) |
| 2 | 11 (7.0) |
| 3 | 2 (1.3) |
| Portal vein thrombosis | |
| Present | 59 (37.6) |
| Absent | 98 (62.4) |
| Extrahepatic spread | |
| Present | 66 (42.0) |
| Absent | 91 (58.0) |
| Prior therapy | |
| Surgery | 65 (27.9) |
| RFA | 41 (17.6) |
| TACE | 109 (46.8) |
| TARE | 66 (28.3) |
| EBRT | 23 (9.9) |
| Systemic therapy line | |
| 1 | 85 (36.5) |
| 2 | 130 (55.8) |
| 3 | 15 (6.4) |
| 4 | 3 (1.3) |
| Alfa-fetoprotein | |
| >400 IU/mL | 132 (56.7) |
| <400 IU/mL | 93 (39.9) |
| Maximum diameter of largest lesion (cm), median (IQR) (n=137) | 5.5 (2.8–8.9) |
ALP, alkaline phosphatase; ALT, alanine transaminase; EBRT, external beam radiotherapy; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis; RFA, radio-frequency ablation; TACE, trans-arterial chemoembolization; TARE, trans-arterial radioembolization.